tbuckley/cabot-search huggingface dataset:
Allogeneic Marrow Stem-Cell Transplantation From Human Leukocyte Antigen–Identical Siblings Versus Human Leukocyte Antigen–Allelic–Matched Unrelated Donors (10/10) in Patients With Standard-Risk Hematologic Malignancy: A Prospective Study From the French Society of Bone Marrow Transplantation and Cell Therapy
Authors: Ibrahim Yakoub-Agha, Florence Mesnil, Mathieu Kuentz, Jean Michel Boiron, Norbert Ifrah, Noel Milpied, Sami Chehata, Helene Esperou, Jean-Paul Vernant, Mauricette Michallet, Agnes Buzyn, Nicole Gratecos, Jean Yves Cahn, Jean Henri Bourhis, Zina Chir, Colette Raffoux, Gerard Socié, Jean Louis Golmard, Jean-Pierre Jouet
Journal: Journal of Clinical Oncology (2006)

To investigate the influence of donor type (human leukocyte antigen [HLA] -identical sibling donor versus HLA-A-, HLA-B-, HLA-Cw-, HLA-DRB1-, and HLA-DQB1-identical unrelated donors, or so-called 10/10) on the outcome of patients who underwent allogeneic stem-cell transplantation (alloSCT), adjusting for other prognostic factors, in patients with standard-risk hematologic malignancy.Between March 2000 and January 2003, we prospectively investigated the outcome of 236 consecutive patients with standard-risk malignancy from 12 French centers. Fifty-five patients underwent alloSCT from an unrelated HLA-identical donor at the allelic level, whereas 181 patients received an alloSCT from an HLA-identical sibling. Diagnoses included acute leukemia (n = 175), chronic myeloid leukemia (n = 43), and myelodysplastic syndrome (MDS; n = 18). All patients received unmodified marrow graft following myeloablative conditioning with cyclophosphamide and total-body irradiation. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and short-course methotrexate in all patients.In multivariable analysis, overall survival and transplantation-related mortality were adversely influenced by recipient cytomegalovirus (CMV) -positive serology, age of donor older than 37 years, and the occurrence of acute grade > or = II GVHD. Event-free survival rates were lower for patients with recipient CMV-positive serology. Acute grades II to IV GVHD rates were higher for patients with chronic myeloid leukemia (CML). No factor was found to influence either relapse or acute grades III to IV GVHD. The effect of donor type was nonsignificant for all criteria.In patients with standard-risk malignancy, transplantation from unrelated HLA-allellically matched donors led to outcomes similar to those from HLA-identical sibling donors.
Prevalence of Alzheimer's Disease in a Community Population of Older Persons
Authors: Denis A. Evans
Journal: JAMA (1989)

Clinically diagnosed Alzheimer's disease and other dementing illnesses were assessed in a geographically defined US community. Of 3623 persons (80.8% of all community residents over 65 years of age) who had brief memory testing in their homes, a stratified sample of 467 persons underwent neurological, neuropsychological, and laboratory examination. Prevalence rates of Alzheimer's disease were calculated for the community population from the sample undergoing clinical evaluation. Of those over the age of 65 years, an estimated 10.3% (95% confidence limits, 8.1% and 12.5%) had probable Alzheimer's disease. This prevalence rate was strongly associated with age. Of those 65 to 74 years old, 3.0% (95% confidence limits, 0.8 and 5.2) had probable Alzheimer's disease, compared with 18.7% (95% confidence limits, 13.2 and 24.2) of those 75 to 84 years old and 47.2% (95% confidence limits, 37.0 and 63.2) of those over 85 years. Other dementing conditions were uncommon. Of community residents with moderate or severe cognitive impairment, 84.1% had clinically diagnosed Alzheimer's disease as the only probable diagnosis. These data suggest that clinically diagnosed Alzheimer's disease is a common condition and that its public health impact will continue to increase with increasing longevity of the population. (<i>JAMA</i>. 1989;262:2551-2556)
VALIDATION OF THREE-DIMENSIONAL ECHOCARDIOGRAPHY FOR QUANTIFICATION OF AORTIC ROOT GEOMETRY; COMPARISON WITH MULTI-DETECTOR COMPUTED TOMOGRAPHY
Authors: Jin-Sun Park, Eun-Jin Han, Sun-Mi Kim, Hyoung-Mo Yang, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Seung-Jea Tahk, Joon-Han Shin
Journal: Journal of the American College of Cardiology (2011)
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Authors: P F Conte, M Bruzzone, F Carnino, A Gadducci, R Algeri, A Bellini, F Boccardo, I Brunetti, E Catsafados, S Chiara, G Foglia, L Gallo, L Iskra, S Mammoliti, G Parodi, N Ragni, R Rosso, S Rugiati, A Rubagotti
Journal: Journal of Clinical Oncology (1996)

PURPOSE The aim of the study was to compare high-versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin as primary chemotherapy for suboptimal stage III and IV ovarian cancer. PATIENTS AND METHODS One hundred forty-five patients were randomized to receive six courses of cisplatin 50 or 100 mg/m2 plus epidoxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2. The two treatment arms were well balanced; all patients had greater than 2 cm and 37.2% had greater than 5 cm of residual disease; 29.6% had stage IV disease. RESULTS Patients in the high-dose arm received a double dose-intensity and double total dose of cisplatin. The high-dose regimen induced significantly more episodes of leukopenia (47.8% v 32.8%, P = .05), thrombocytopenia (21.7% v 3.2%, P = .003), anemia (37.6% v 12.5%, P = .002), nephrotoxicity (six v one patient), and neurotoxicity (30.4% v 6.3%, P = .002). There were no significant differences in efficacy in terms of clinical response rate (high-dose 57.5% v low-dose 61.1%), pathologic complete response (CR) (9.6% v 18.1%), median survival times (29 v 24 months), and median progression-free survival (18 v 13 months). CONCLUSION This study shows that doubling the dose-intensity and total dose of cisplatin in combination with epidoxorubicin and cyclophosphamide has significant toxic effects and does not improve clinical outcome in patients with suboptimal ovarian cancer.
Continuum Mixture Models of Biological Growth and Remodeling: Past Successes and Future Opportunities
Authors: G.A. Ateshian, J.D. Humphrey
Journal: Annual Review of Biomedical Engineering (2012)

Biological growth processes involve mass exchanges that increase, decrease, or replace material that constitutes cells, tissues, and organs. In most cases, such exchanges alter the structural makeup of the material and consequently affect associated mechanobiological responses to applied loads. Given that the type and extent of changes in structural integrity depend on the different constituents involved (e.g., particular cytoskeletal or extracellular matrix proteins), the continuum theory of mixtures is ideally suited to model the mechanics of growth and remodeling. The goal of this review is twofold: first, to highlight a few illustrative examples that show diverse applications of mixture theory to describe biological growth and/or remodeling; second, to identify some open problems in the fields of modeling soft-tissue growth and remodeling.
Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database
Authors: Natasha M. Rueth, Heather Y. Lin, Isabelle Bedrosian, Simona F. Shaitelman, Naoto T. Ueno, Yu Shen, Gildy Babiera
Journal: Journal of Clinical Oncology (2014)

To analyze factors that predict the use of trimodality treatment (chemotherapy, surgery, and radiation therapy [RT]) and evaluate the impact that trimodality treatment use has on survival for patients with inflammatory breast cancer (IBC).
Natural History Of Esophageal Remodeling In Pediatric Eosinophilic Esophagitis Treated For Four Years
Authors: Jessica Rajan, Robert Newbury, Arjun Andrew Anilkumar, Ranjan Dohil, David H. Broide, Seema Sharma Aceves
Journal: Journal of Allergy and Clinical Immunology (2014)

RATIONALE: Dermatophagoides pteronyssinus (Der p) and Blomia tropicalis (Blo t) are respiratory allergens that represent a major cause of allergic asthma.Placental transfer and breastfeeding are potential routes of allergen exposure in very early life.To date, no study has demonstrated the presence of those respiratory allergens in paired samples of human cord blood and breast milk samples.METHODS: We assessed whether Der p 1 and Blo t 5 allergens and were transferred through placenta and colostrums in the presence of specific antibodies.The maternal transfer was analyzed in a cohort of 91 paired samples of colostrum and umbilical cord blood.RESULTS: We detect Der p 1 and Blo t 5 in 29% and 9,6% of cord blood samples (median 62.2pg/mL and 892.4pg/ml, respectively).In colostrum 58.6% of samples were positive for Der p 1 and 41.3% for Blo t 5 (range 0-869.9pg/mLand 0-1281pg/ml, respectively).Der p and Blo t-specific IgG1, IgG2, IgG3 and IgG4 were present in cord blood of almost all neonates in a wide range of values, but strongly correlated to maternal levels.More than 90% of cord blood samples were positive for specific IgM, for both allergens.In colostrums, specific IgA and IgG levels were also variable among samples.CONCLUSIONS: We demonstrated that respiratory allergen can be transferred trough placenta and colostrums and that the first actively stimulates the neonate immune system intra uterus.Those observations bring new hypothesis in understanding causal pathway of allergic airway sensitization and raise questions for future strategies for prevention of allergic disease.
IL-2 Costimulation Enables Statin-Mediated Activation of Human NK Cells, Preferentially through a Mechanism Involving CD56+ Dendritic Cells
Authors: Georg Gruenbacher, Hubert Gander, Oliver Nussbaumer, Walter Nussbaumer, Andrea Rahm, Martin Thurnher
Journal: Cancer Research (2010)

Statins are inhibitors of cholesterol biosynthesis and protein prenylation that also have been studied in cancer therapy and chemoprevention. With regard to natural killer (NK) cells, only inhibitory effects of statins such as suppression of granule exocytosis have been reported so far. In this study, we show that statins can cooperate with IL-2 to potently induce the activation of CD56(dim) NK cells in a synergistic, time- and dose-dependent fashion. Supplementation experiments revealed that the statin effect was specific to inhibition of their target hydroxymethylglutaryl coenzyme A reductase and that downstream depletion of geranylgeranyl pyrophosphate was responsible for cooperating with IL-2 in NK cell activation. Mechanistic studies revealed that CD56(+)HLA-DR(+)CD14(+) dendritic cell (DC)-like accessory cells mediated the ability of statin to activate NK cells. In contrast, BDCA-1(+) (CD1c(+)) myeloid DCs, which partially expressed CD56, were somewhat less potent. Conventional blood monocytes, which lack CD56, exhibited the lowest accessory cell capacity. NK cell IFN-γ production was IL-12 independent but required endogenous IL-18, IL-1β, and caspase-1 activity. Statins directly induced apoptosis in human cancer cell lines and cooperated with NK cell-derived IFN-γ to generate potent cytotoxic antitumor effects in vitro even in the presence of statin-mediated inhibitory effects on granule exocytosis. Our work reveals novel and unexpected immunomodulatory properties of statins, which might be harnessed for the treatment of cancer.
Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 Disease
Authors: Forbes D. Porter, David E. Scherrer, Michael H. Lanier, S. Joshua Langmade, Vasumathi Molugu, Sarah E. Gale, Dana Olzeski, Rohini Sidhu, Dennis J. Dietzen, Rao Fu, Christopher A. Wassif, Nicole M. Yanjanin, Steven P. Marso, John House, Charles Vite, Jean E. Schaffer, Daniel S. Ory
Journal: Science Translational Medicine (2010)

Oxysterols are biomarkers for diagnosis and drug treatment in Niemann-Pick C1 disease.
Fecal Coliform Testing to Identify Effective Antibiotic Therapies for Patients With Antibiotic-Resistant Pouchitis
Authors: Simon D. McLaughlin, Susan K. Clark, Suja Shafi, Liljana Petrovska, Paris P. Tekkis, Paul J. Ciclitira, R. John Nicholls
Journal: Clinical Gastroenterology and Hepatology (2009)
CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA
Authors: Alice Conigliaro, Viviana Costa, Alessia Lo Dico, Laura Saieva, Simona Buccheri, Francesco Dieli, Mauro Manno, Samuele Raccosta, Carmine Mancone, Marco Tripodi, Giacomo De Leo, Riccardo Alessandro
Journal: Molecular Cancer (2015)

CD90+ liver cancer cells have been described as cancer stem-cell-like (CSC), displaying aggressive and metastatic phenotype. Using two different in vitro models, already described as CD90+ liver cancer stem cells, our aim was to study their interaction with endothelial cells mediated by the release of exosomes. Exosomes were isolated and characterized from both liver CD90+ cells and hepatoma cell lines. Endothelial cells were treated with exosomes, as well as transfected with a plasmid containing the full length sequence of the long non-coding RNA (lncRNA) H19. Molecular and functional analyses were done to characterize the endothelial phenotype after treatments. Exosomes released by CD90+ cancer cells, but not by parental hepatoma cells, modulated endothelial cells, promoting angiogenic phenotype and cell-to-cell adhesion. LncRNA profiling revealed that CD90+ cells were enriched in lncRNA H19, and released this through exosomes. Experiments of gain and loss of function of H19 showed that this LncRNA plays an important role in the exosome-mediated phenotype of endothelial cells. Our data indicate a new exosome-mediated mechanism by which CSC-like CD90+ cells could influence their tumor microenvironment by promoting angiogenesis. Moreover, we suggest the lncRNA H19 as a putative therapeutic target in hepatocellular carcinoma.
Improving Type 1 Diabetes After Treatment of Immune Thrombocytopenia With Rituximab: Killing Two Birds With One Stone
Authors: Laura Quintana, Juan A. Paniagua, Daniel Gil-Contreras, Victor Jimenez-Yuste, Antonio Torres, Francisco Velasco
Journal: Diabetes Care (2010)

Rituximab, a monoclonal antibody (mAb) specific for human CD20 expressed on the surface of B-cells, has been used to treat patients with B-cell–mediated diseases such as B-cell lymphomas, immune thrombocytopenia (ITP), and other autoimmune diseases. It was recently also used to treat patients diagnosed with type 1 diabetes (1,2). Although type 1 diabetes is considered an autoimmune T-cell–mediated disease, B-cells do play a role in its development by both secreting autoantibodies specific for islet cell proteins (used as markers of the disease) and acting as antigen-presenting cell population for T-CD4+ cells (3). In fact, a recent clinical trial demonstrated the effectiveness of rituximab in the treatment …
Acute sporadic non-A, non-B, non-C, non-D, non-E hepatitis
Authors: F A Rochling, W F Jones, K Chau, L DuCharme, L T Mimms, B Moore, J Scheffel, J A Cuthbert, D L Thiele
Journal: Hepatology (1997)

ABSTRACT Patients presenting with clinical and laboratory features consistent with a diagnosis of acute non–A, non–B hepatitis were evaluated for evidence of hepatitis C or hepatitis E infection and for evidence of severe or prolonged disease. Antibody to hepatitis C virus (anti–HCV) was detected in 75 of 108 (69%) patients, antibody to hepatitis E virus (anti–HEV) in three patients (3%), and neither antibody in 31 (29%) patients. One patient had both anti–HCV and anti–HEV. HCV RNA was not detected in sera from any of 20 patients with seronegative (non–ABCDE) hepatitis, but in all 10 patients with anti–HCV who were tested by polymerase chain reaction (PCR). Compared with patients with acute hepatitis C, those with non–ABCDE hepatitis had a lower incidence of parenteral risk factors (6% vs. 70%; P &lt; .001), higher peak serum bilirubin levels (45% vs. 5% with peak levels &gt; 15 mg/dL; P &lt; .001), more prolonged jaundice (25% vs. 0% with peak bilirubin &gt;5 weeks after onset; P &lt; .01), more severe prothrombin time abnormalities (26% vs. 0% with &gt;3 second prolongation; P &lt; .001), more severe hypoalbuminemia (39% vs. 9% with albumin &lt;3 g/dL; P &lt; .01), and more frequent major clinical complications (13% vs. 0% with encephalopathy; P &lt; .01; 10% vs. 0% with death or transplant; P = .024). Patients with acute non–ABCDE hepatitis were less likely to develop chronic hepatitis than those with acute hepatitis C (23% vs. 68%; P &lt; .05). Thus, patients with acute non–ABCDE hepatitis are epidemiologically distinct from those with acute hepatitis C and have a significantly more severe acute illness.
Identification of a Novel Estrogen-Regulated Gene, <i>EIG121</i>, Induced by Hormone Replacement Therapy and Differentially Expressed in Type I and Type II Endometrial Cancer
Authors: Lei Deng, Russell R. Broaddus, Adrienne McCampbell, Gregory L. Shipley, David S. Loose, George M. Stancel, James H. Pickar, Peter J.A. Davies
Journal: Clinical Cancer Research (2005)

Abstract Purpose: The identification of genes and pathways that are affected by estrogenization may shed light on the mechanisms of estrogen action. Here, we describe the expression pattern of a novel estrogen-induced gene, EIG121, in distinct types of endometrial cancer. Experimental Design: EIG121 was identified by cDNA microarray analysis of endometrial RNA from women receiving either placebo or estrogen replacement therapy. The expression level of EIG121 was then measured by real-time quantitative reverse transcription-PCR in benign, hyperplastic, and malignant endometrial samples. A polyclonal antibody was used to detect EIG121 protein by immunohistochemistry. Results: In postmenopausal endometrium, estrogen replacement therapy with Premarin and synthetic estrogen sulfate conjugates induced the expression of EIG121 2- and 3-fold, respectively. In premenopausal endometrium, the expression of EIG121 was higher in the estrogen-dominated proliferative phase than the secretory phase. In endometrial complex, hyperplasia, and endometrioid adenocarcinoma, neoplastic proliferations associated with estrogen excess, the expression of EIG121 was significantly elevated (on average 3.8-fold in hyperplasias and 21-fold in grade 1 tumors). Although the level of EIG121 mRNA in grade 3 endometrioid carcinoma was still 3.5-fold of that in benign endometrium, EIG121 expression tended to decline with increasing tumor grade and disease stage. Immunohistochemistry showed faint staining of normal endometrial epithelium, but intense staining of endometrioid tumors. In sharp contrast, EIG121 expression was significantly suppressed in both uterine papillary serous carcinoma and uterine malignant mixed mullerian tumor, two tumors not associated with estrogen exposure, to &amp;lt;5% of the level in benign endometrium. Conclusions: Our results suggest that EIG121 is a good endometrial biomarker associated with a hyperestrogenic state and estrogen-related type I endometrial adenocarcinoma.
Peak or plateau maximal inspiratory mouth pressure: which is best?
Authors: W. Windisch, E. Hennings, S. Sorichter, H. Hamm, C.P. Criée
Journal: European Respiratory Journal (2004)

There is no clear evidence as to how maximal inspiratory mouth pressure (PI,max) should be measured, although plateau pressures sustained for 1 s and measured at residual volume (RV) are usually recommended. Peak and plateau PI,max were measured at RV and at functional residual capacity (FRC) in 533 healthy subjects (aged 10-90 yrs) in order to comparably test all PI,max measurements for their predictors, reproducibility and normal values. Plateau pressures accounted for 82.0-86.3%, of peak pressures. Peak and plateau pressures measured at FRC accounted for 84.3-90.5% of pressures at RV, and were highly correlated. Age was negatively predictive and weight and body mass index positively predictive of PI,max, but regression parameters were low. All PI,max measurements were comparable when calculating regression parameters, between-subject variability and reproducibility. In conclusion, peak and plateau maximal inspiratory mouth pressure are comparably useful for the assessment of inspiratory muscle strength and can be reliably measured at functional residual capacity and at residual volume. Regression equations are of low impact in predicting normal values due to the weak influence of demographic and anthropometric factors and to the high unexplained between-subject-variability. Age-related 5th percentiles can indicate the lower limit of the normal range.
Treatment of Pulmonary Metastases in Children With Stage IV Nephroblastoma With Risk-Based Use of Pulmonary Radiotherapy
Authors: Arnauld Verschuur, Harm Van Tinteren, Norbert Graf, Christophe Bergeron, Bengt Sandstedt, Jan de Kraker
Journal: Journal of Clinical Oncology (2012)

Purpose The purpose of this study was to determine the outcome of children with nephroblastoma and pulmonary metastases (PM) treated according to International Society of Pediatric Oncology (SIOP) 93-01 recommendations using pulmonary radiotherapy (RT) in selected patients. Patients and Methods Patients (6 months to 18 years) were treated with preoperative chemotherapy consisting of 6 weeks of vincristine, dactinomycin, and epirubicin or doxorubicin. If pulmonary complete remission (CR) was not obtained, metastasectomy was considered. Patients in CR received three-drug postoperative chemotherapy, whereas patients not in CR were switched to a high-risk (HR) regimen with an assessment at week 11. If CR was not obtained, pulmonary RT was mandatory. Results Two hundred thirty-four of 1,770 patients had PM. Patients with PM were older (P &lt; .001) and had larger tumor volumes compared with nonmetastatic patients (P &lt; .001). Eighty-four percent of patients were in CR postoperatively, with 17% requiring metastasectomy. Thirty-five patients (16%) had multiple inoperable PM and required the HR protocol. Only 14% of patients received pulmonary RT during first-line treatment. For patients with PM, 5-year event-free survival rate was 73% (95% CI, 68% to 79%), and 5-year overall survival (OS) rate was 82% (95% CI, 77% to 88%). Five-year OS was similar for patients with local stage I and II disease (92% and 90%, respectively) but lower for patients with local stage III disease (68%; P &lt; .001). Patients in CR after chemotherapy only and patients in CR after chemotherapy and metastasectomy had a better outcome than patients with multiple unresectable PM (5-year OS, 88%, 92%, and 48%, respectively; P &lt; .001). Conclusion Following the SIOP protocol, pulmonary RT can be omitted for a majority of patients with PM and results in a relatively good outcome.